IKT

Inhibikase Therapeutics, Inc. (NASDAQ:IKT) is a clinical-stage pharmaceutical company founded in 2008 and headquartered in Atlanta, Georgia. The company went public in December 2020 and focuses on developing innovative therapeutics for neurological disorders, particularly Parkinson's disease and related conditions. Inhibikase has built its research foundation through collaborations with prestigious academic institutions including Johns Hopkins University, Arizona State University, Michigan State University, and Louisiana State University. The company operates as a development-stage biotechnology firm with no current revenue from product sales, instead relying on research grants and investor funding to advance its pipeline of experimental treatments.